In a mouse model, the PERK inhibitor GSK2656157 synergistically inhibited the growth of colon cancer cells with 5-FU, a commonly used first-line chemotherapeutic agent for advanced colon cancer patients. The gene discussed is EIF2AK3; the disease is malignant colon neoplasm.